EA201390653A1 - Aa антагонисты как усилители когнитивной и моторной функций - Google Patents

Aa антагонисты как усилители когнитивной и моторной функций

Info

Publication number
EA201390653A1
EA201390653A1 EA201390653A EA201390653A EA201390653A1 EA 201390653 A1 EA201390653 A1 EA 201390653A1 EA 201390653 A EA201390653 A EA 201390653A EA 201390653 A EA201390653 A EA 201390653A EA 201390653 A1 EA201390653 A1 EA 201390653A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cognitive
motor functions
antagonists
amplifiers
adenosine
Prior art date
Application number
EA201390653A
Other languages
English (en)
Other versions
EA035900B1 (ru
Inventor
Стефен И. Бэндэк
Кевин Дж. Блэк
Меган К. Кемпбелл
Original Assignee
Байотай Терапис, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байотай Терапис, Инк. filed Critical Байотай Терапис, Инк.
Publication of EA201390653A1 publication Critical patent/EA201390653A1/ru
Publication of EA035900B1 publication Critical patent/EA035900B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Описаны способы для индуцирования когнитивной и моторной функций у пациентов, страдающих болезнью Паркинсона, путем введения эффективного количества Аденозин 2а антагониста. Аденозин 2а антагонист можно опционально вводить в комбинации с предшественником допамина, таким как леводопа, или агонистом допаминовых рецепторов.
EA201390653A 2010-11-05 2011-11-04 Применение (4-метокси-7-морфолин-4-ил-бензотиазол-2-ил)амида 4-гидрокси-4-метилпиперидин-1-карбоновой кислоты для лечения сонливости, связанной с болезнью паркинсона EA035900B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2010/055681 WO2012060844A1 (en) 2010-11-05 2010-11-05 A2a antagonists as cognition and motor function enhancers
PCT/US2011/059466 WO2012061787A1 (en) 2010-11-05 2011-11-04 A2a antagonists as cognition and motor function enhancers

Publications (2)

Publication Number Publication Date
EA201390653A1 true EA201390653A1 (ru) 2013-12-30
EA035900B1 EA035900B1 (ru) 2020-08-28

Family

ID=46024745

Family Applications (2)

Application Number Title Priority Date Filing Date
EA202091356A EA202091356A1 (ru) 2010-11-05 2011-11-04 A2a АНТАГОНИСТЫ КАК УСИЛИТЕЛИ КОГНИТИВНОЙ И МОТОРНОЙ ФУНКЦИЙ
EA201390653A EA035900B1 (ru) 2010-11-05 2011-11-04 Применение (4-метокси-7-морфолин-4-ил-бензотиазол-2-ил)амида 4-гидрокси-4-метилпиперидин-1-карбоновой кислоты для лечения сонливости, связанной с болезнью паркинсона

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA202091356A EA202091356A1 (ru) 2010-11-05 2011-11-04 A2a АНТАГОНИСТЫ КАК УСИЛИТЕЛИ КОГНИТИВНОЙ И МОТОРНОЙ ФУНКЦИЙ

Country Status (15)

Country Link
US (2) US20130317019A1 (ru)
EP (1) EP2635256B1 (ru)
JP (3) JP6315991B2 (ru)
KR (2) KR101955045B1 (ru)
CN (3) CN107281491A (ru)
AU (3) AU2011323152A1 (ru)
BR (1) BR112013011068A2 (ru)
CA (1) CA2816834A1 (ru)
EA (2) EA202091356A1 (ru)
ES (1) ES2842968T3 (ru)
HK (1) HK1245138A1 (ru)
IL (2) IL225868B (ru)
MX (1) MX2013005014A (ru)
NZ (2) NZ609803A (ru)
WO (2) WO2012060844A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6339758B2 (ja) * 2012-07-02 2018-06-06 国立研究開発法人国立長寿医療研究センター 軽度認知機能障害の有無の診断システム、認知機能検査用端末及び認知機能検査用プログラム
JO3544B1 (ar) 2015-03-19 2020-07-05 Kyowa Kirin Co Ltd عامل علاجي للاختلال الوظيفي في الفص الجبهي
AU2016278846B2 (en) 2015-06-19 2021-08-05 Biotie Therapies, Inc. Controlled-release tozadenant formulations
WO2018013951A1 (en) * 2016-07-15 2018-01-18 Northwestern University Targeting adenosine a2a receptors for the treatment of levodopa-induced dyskinesias
WO2018059531A1 (zh) * 2016-09-30 2018-04-05 苏州晶云药物科技有限公司 一种腺苷a2a受体拮抗剂药物的晶型及其制备方法和用途
WO2021113266A1 (en) * 2019-12-02 2021-06-10 Sinopia Biosciences, Inc. Treating cognitive disorders using trapidil

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4376630B2 (ja) * 2002-01-28 2009-12-02 協和発酵キリン株式会社 運動障害治療剤
EA011279B1 (ru) * 2004-05-24 2009-02-27 Ф. Хоффманн-Ля Рош Аг (4-метокси-7-морфолин-4-илбензотиазол-2-ил)-амид 4-гидрокси-4-метилпиперидин-1-карбоновой кислоты
US7576073B2 (en) * 2004-05-28 2009-08-18 UNIVERSITé LAVAL Combined therapy for the treatment of parkinson's disease
US8168785B2 (en) * 2009-06-17 2012-05-01 Biotie Therapies, Inc. Benzothiazole derivatives

Also Published As

Publication number Publication date
KR20130143597A (ko) 2013-12-31
US20220125772A1 (en) 2022-04-28
CN107281491A (zh) 2017-10-24
EA035900B1 (ru) 2020-08-28
KR20190025734A (ko) 2019-03-11
JP6611896B2 (ja) 2019-11-27
JP6444951B2 (ja) 2018-12-26
EP2635256A4 (en) 2014-05-21
IL225868B (en) 2019-05-30
EA202091356A1 (ru) 2020-12-30
CA2816834A1 (en) 2012-05-10
WO2012061787A1 (en) 2012-05-10
EP2635256A1 (en) 2013-09-11
HK1245138A1 (zh) 2018-08-24
MX2013005014A (es) 2014-01-31
CN103429221A (zh) 2013-12-04
JP2017019829A (ja) 2017-01-26
US20130317019A1 (en) 2013-11-28
KR101955045B1 (ko) 2019-03-06
NZ609803A (en) 2016-08-26
NZ746118A (en) 2020-03-27
AU2018286608A1 (en) 2019-01-24
CN109223799A (zh) 2019-01-18
IL225868A0 (en) 2013-07-31
JP2013541593A (ja) 2013-11-14
JP2019052163A (ja) 2019-04-04
WO2012060844A1 (en) 2012-05-10
AU2011323152A1 (en) 2013-06-06
EP2635256B1 (en) 2020-10-21
KR102166229B1 (ko) 2020-10-15
IL266321A (en) 2019-06-30
AU2018286608B2 (en) 2020-07-30
JP6315991B2 (ja) 2018-04-25
ES2842968T3 (es) 2021-07-15
AU2017201446A1 (en) 2017-03-23
BR112013011068A2 (pt) 2016-08-23

Similar Documents

Publication Publication Date Title
EA201390977A1 (ru) Комбинация агониста опиоидных рецепторов и антагониста опиоидных рецепторов для лечения болезни паркинсона
MX2010004281A (es) Composiciones y metodos para el tratamiento de la retinopatia diabetica.
EA201300869A1 (ru) Морфинановые соединения
ME01532B (me) Jedinjenja
EA201270467A1 (ru) Полициклические соединения в качестве антагонистов рецепторов лизофосфатидной кислоты
EA201101709A1 (ru) Полициклические антагонисты рецепторов лизофосфатидной кислоты
MY169479A (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
EA201390653A1 (ru) Aa антагонисты как усилители когнитивной и моторной функций
CL2012003604A1 (es) Compuestos heterociclicos derivados de piridina carboxamida sustituida; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; uso en el tratamiento de trastornos proliferativos celulares, enfermedad de parkinson, cancer, entre otros.
EA201270767A1 (ru) Терапия на основе лигандов хемосенсорных рецепторов
MX341482B (es) Antagonistas del receptor ep4 y su uso en el tratamiento de enfermedades mediadas por la il-23.
EA201390821A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты и их применение
BR112012020273A2 (pt) Compostos de pirazolopiridina, pirazolopirazina, pirazolopirimidina, pirazolotiofeno e pirazolotiazol como pontencializadores alostéricos de mglur4, composições e métodos de tratamento de disfunção neurológica
EA201001253A1 (ru) N,n-дизамещенные аминоалкилбифенилы в качестве антагонистов рецепторов простагландина d
EA201170940A1 (ru) Лечение рака с использованием комбинации бендамустина и анти-cd20-антитела
EA201290266A1 (ru) Комбинации антагониста мускариновых рецепторов и агониста бета-2-адренорецепторов
EA201391581A1 (ru) Способы лечения болезни альцгеймера, болезни хантингтона, аутизма и других расстройств
CL2013003484A1 (es) Compuestos derivados de n-(4-morfolin-2-il)fenil)-1h-pirazol-(3 o 5)-carboxamida o n-(4-piperidin-3-il)fenil)-1h-pirazol-(3 o 5)-carboxamida afines a receptores asociados a taar1; procedimiento de preparacion; composicion farmaceutica y uso en el tratamiento y/o la profilaxis de enfermedades tales como depresion, trastorno bipolar, alzheimer y parkinson, entre otras.
MY156288A (en) Pharmaceutical formulations containing dopamine receptor ligands.
CY1119560T1 (el) Μεθοδοι για μειωση αδηφαγικης διαταραχης ή ψυχαναγκαστικης υπερφαγιας
MX348933B (es) Composiciones, formas de dosificacion y coadministracion de un compuesto agonista opioide y un compuesto analgesico.
MX2013006418A (es) Derivados de oxazolil-metileter como agonistas del receptor de alx.
BR112013009004A2 (pt) combinações de agonistas de receptor de serotonina para o tratamento de distúrbios de movimento
MA35816B1 (fr) Dérivés d'aniline, leur préparation et leur application thérapeutique

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM